Epidermal basement membrane α5(IV) expression in females with Alport syndrome and severity of renal disease  by Massella, Laura et al.
Kidney International, Vol. 64 (2003), pp. 1787–1791
CLINICAL NEPHROLOGY – EPIDEMIOLOGY – CLINICAL TRIALS
Epidermal basement membrane 5(IV) expression in females
with Alport syndrome and severity of renal disease
LAURA MASSELLA, ANDREA ONETTI MUDA, TULLIO FARAGGIANA, CRISTIANO BETTE,
ALESSANDRA RENIERI, and GIANFRANCO RIZZONI
Division of Nephrology and Dialysis, Bambino Gesu` Children’s Hospital and Research Institute, Rome, Italy;
Department of Pathology, University La Sapienza, Rome, Italy; and Medical Genetics, University of Siena, Siena, Italy
Epidermal basement membrane 5(IV) expression in females
with Alport syndrome and severity of renal disease.
Background. X-linked Alport syndrome is a progressive ne-
phritis caused by mutations of the COL4A5 gene. This gene
encodes the collagen 5(IV) chain, which is abnormally distrib-
uted in the glomerular basement membrane (GBM) and epi-
dermal basement membrane (EBM). It has been reported a
negative correlation between5(IV) chain distribution in EBM
and the degree of proteinuria in heterozygous females with
Alport syndrome.
Methods. In the present study, we evaluated the distribution
of the 5(IV) chain in the EBM and the degree of proteinuria
in 22 females with X-linked Alport syndrome. The distribution
of the cutaneous 5(IV) chain was measured by a confocal
laser microscope using an anti-5(IV) monoclonal antibody.
The expression ratio of 5(IV) distribution was quantified di-
viding the extension of the positive signal and the maximal
extension of the specimen. Urinary protein excretion was ex-
pressed as urinary protein over urinary creatinine ratio.
Results. Proteinuria was present in five of the 22 patients.
In two patients with proteinuria, 5(IV)chain was normally dis-
tributed; in the remaining three, the expression ratio of 5(IV)-
chain was 35%, 47%, and 48%. Of the 17 patients without pro-
teinuria, two displayed a complete absence of the 5(IV) chain
in EBM, five displayed a normal staining, and the remaining
10 had an expression ratio between 18% and 65%.
Conclusion. Our data suggest that there is no correlation
between the severity of the glomerular involvement (expressed
by proteinuria) and the staining of the 5 chain in the EBM
in females with X-linked Alport syndrome.
Alport syndrome is a disorder of the glomerular base-
ment membrane (GBM) characterized by haematuria,
proteinuria, and progressive renal failure. It is often asso-
ciated with bilateral sensorineural deafness and, less fre-
quently, with ocular lesions. Most Alport families dem-
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onstrate X-linked inheritance. In general, the clinical and
histologic phenotype is more severe in males and is vari-
able in female patients, ranging from normal urine to
chronic renal failure [1]. Type IV collagen is the main
component of basement membranes and includes six
distinct  chains, termed 1 to 6. These are encoded by
six different genes, termed COL4A1 to COL4A6 [2–6].
 chains distribution is tissue specific. The chains 1
to 5 are expressed in the GBM and form triple helical
molecules that self assemble to form supramolecular net-
works. In the epidermal basement membrane (EBM),
the 5 chain is expressed together with 1, 2, and 6,
whereas the 3 and 4 chains are absent [7, 8]. In
X-linked Alport syndrome, mutations of the COL4A5
gene generally, but not always, result in the loss of the
5(IV) chain in basement membranes. In the kidney,
this can be associated with the absence of 3 and 4
chains despite an increased production of 1 and 2
chains [9]. The complete absence of the 5 chain is more
frequent in male patients, while in females the distribu-
tion is more often segmental [10]. In the EBM, male
patients lack the 5 chain, while several immunohisto-
chemical studies have shown a segmental distribution in
heterozygous females [10] [abstract; Massella L, J Am
Soc Nephrol 10:A2213, 1999].
Nakanishi et al [11], in a mostly adult female popula-
tion of Alport syndrome, all with segmental expression of
the 5 chain, found a negative correlation between the
degree of proteinuria and 5 expression levels in the skin.
We report different results on a cohort of 22 female
patients that included cases with absent as well as normal
protein expression.
METHODS
We studied 22 symptomatic and obligate carrier fe-
males from 17 different families with X-linked Alport
syndrome. The diagnosis was based on at least two of
the following criteria: (1) family history of haematuria
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Fig. 1. Pedigree of patients 2 and 9. All the affected males reached
end-stage renal disease (ESRD) before the age of 31 years. The genea-
logical tree is compatible with an X-linked semidominant transmission
disease. Black squares indicate affected males; gray circles indicate
heterozygous symptomatic females.
with or without renal failure, (2) typical ultrastructural
picture of the GBM in renal biopsy performed on the
female or on a symptomatic male relative, (3) partial or
complete lack of the 5(IV) chain in the EBM, and (4)
identification of a mutation on the COL4A5 gene. Four
criteria were present in nine patients, three in six pa-
tients, and two in seven patients. One of the criteria (2, 3,
or 4) was always present in each patient. A mutation was
found in 16 patients from 13 different families (Table 1).
Family history was negative only in two patients (patients
6 and 7) and a de novo mutation on the COL4A5 gene
was identified in both of them. Patient 3 had six male
cousins with histologically demonstrated Alport syn-
drome and is the mother of patient 4. No mutation was
identified on the COL4A5 gene in this patient, but her
genealogic tree demonstrated an X-linked transmission
(Fig. 1). All patients had normal renal function and mi-
crohaematuria, which was inconstant in only one case.
Twelve patients (patients 2, 4 to 9, 11, 13, 14, 19, and
20) had no ocular abnormalities and the remaining 10
were not examined. Two patients had sensorineural deaf-
ness (patients 13 and 19), while in 14 (patients 1, 2, 4 to
9, 11, 12, 14, 15, 20, and 22), the audiogram was within
normal limits. In the remaining six patients, an audio-
gram was not available. Urinary protein (mg/dL) over
creatinine (mg/dL) ratio was used to assess the degree
of proteinuria. The value reported in the results is the
mean value obtained from three consecutive morning
samples. Proteinuria was measured by a colorimetric
method (Hitachi).
Skin biopsies were performed at the axillary fold in
19 patients with a 3 mm punch. In three, skin biopsy was
performed in the lumbar region during percutaneous
renal biopsy. Mean age at biopsy was 26.6 years (from
2 to 64 years).
In six patients (patients 6 to 9, 14, and 16), a renal
biopsy was also performed, but only in four of them
(patients 7 to 9 and 14) the immunohistochemical study
for the 5(IV) chain was available (Tables 1 and 2). In
Table 1, 5 distribution in EBM and in GBM in related
males are also reported. Informed consent was obtained
from all patients and/or their parents.
Immunohistochemical study
Skin samples at biopsy were embedded in 22-oxacalci-
triol (OCT), snap frozen in liquid nitrogen–cooled iso-
pentane and stored at 80C until used. In four cases,
frozen renal biopsy tissue was also available for an immu-
nohistochemical study.
Ten samples of normal skin were obtained as controls
at surgery from patients with malignant tumors (squa-
mous cell carcinoma or melanoma). Monoclonal anti-
bodies against 1(IV) and 5(IV) chains were purchased
from Weislab AB (Lund, Sweden); a fluorescein isothio-
cyanate (FITC)-conjugated secondary antimouse anti-
body was obtained from Dako Corp. (Glostrup, Den-
mark). Skin tissue was incubated with antibodies against
1(IV) and 5(IV).
Four micron cryostat sections of frozen tissue(s) were
fixed in acetone and stained by indirect method; primary
antibodies were diluted 1:50 (5 chain) in phosphate-
buffered saline (PBS). Incubation was carried out for
1 hour at room temperature and was followed by 30
minutes of incubation with a 1:20 solution of a secondary
antibody. The sections for 5(IV) immunostaining were
denatured in 6 mol/L urea 0.1 glycine HCl buffer, pH
3.5, 30 minutes at room temperature, before the immune
reaction. At least two sections taken at different levels
of the frozen specimen of all patients and controls were
independently examined by two observers with a Nikon
microscope equipped with epifluorescence illumination
optics. No significant variations in staining were observed.
The length of the EBM displaying positive staining
with the anti-5(IV) antibody and the total length of the
EBM was measured using a confocal laser scanning mi-
croscope (CLSM) (Sarastro 2000, Molecular Dynamics,
Buckinghamshire, UK). Briefly, a single scan was per-
formed along the focal plane displaying the highest signal
intensity; maximal extension of the specimen and exten-
sion of the positive signal were measured using Measure-
ment Functions of Image Space software (Molecular Dy-
namics). The expression ratio was calculated dividing
the former by the latter.
Genetic analysis
COL4A5 mutation genes were identified by polymer-
ase chain reaction (PCR)-single-strand conformational
polymorphism (SSCP) analysis and direct sequencing [12].
Statistical analyses
Correlation between distribution of the 5(IV) chain
in the EBM and urinary protein over creatinine excretion
ratio was evaluated with the Spearman rank correlation
coefficient.
RESULTS
Urinary protein excretion and immunohistochemical
results are summarized in Table 2. Proteinuria at the time
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Table 1. Distribution of the diagnosic criteria
EM in
female
Renal patient or 5 (EBM) 5 (GBM)
Family biopsy in related in related in related Mutation in
Patient history years males males males COL4A5
1Ma  NA Typical Absent Absent gly828/arg
2Ma  NA Typical Absent Absent gly828/arg
3Ba  NA Typical NA NA NI
4Ba  NA Typical NP NA NI
5  NA NA NA NA gly1107/arg
6  Yes [12] Typical NA NA Ex7 ins 4 bp(18)
7  Yes [8] Typical NA NA Ex21 del 9 bp(12)
8  Yes [18] Typical NA NA gly54/asp(19)
9  Yes [16] Typical NA NA gly1379/val812)
10  NA Typical Absent NA NI
11  NA Typical Absent NA NI
12  NA Typical Absent Absent NI
13  NA Typical Absent Absent gly781/STOP
14  Yes [5] Typical Absent NA gly1107/arg
15Fa  NA Typical Absent NA NI
16Fa  Yes [25] Typical Absent NA NI
17La  NA NA Absent NA gly1214/stop
18La  NA NA Absent NA gly1214/stop
19  NA Typical Segmental Absent del ex 2-25(20)
20Da  NA Typical Absent Absent del C 2259
21Da  NA Typical Absent Absent del C 2259
22  NA Typical Absent Absent gly988/glu
Abbreviations are: EBM, epidermal basement membrane; GBM, glomerular basement membrane; NA, not available; NI, not identified; EM, electron microscopy.
a The same letter indicates patients belonging to the same family
Table 2. Results
Urinary protein
5(IV)
Age at expression 5(IV)
skin Actual ratio in in
Patient biopsy age Urinary creatinine EBM % GBM
1Ma 41 43 0.35 47
2Ma 10 12 1.09 35
3Ba 32 35 0.36 100
4Ba 2 5 — 100
5 3 5 0.58 48
6 18 21 1.58 100 NA
7 17 19 — 100 Diffuse
8 19 21 — 0 Absent
9 12 17 — 0 Diffuse
10 46 43 — 100
11 4 7 — 18
12 43 44 — 20
13 37 40 — 18
14 5 7 — 100 Diffuse
15Fa 64 66 — 40
16Fa 32 35 — 55
17La 33 35 — 100
18La 31 33 — 35
19 51 53 — 23
20 7 8 — 30
21 32 33 — 60
22 43 44 — 65
For abbreviations, see Table 1.
a The same letter indicates patients belonging to the same family
of skin biopsy was present in five of the 22 patients and
urinary protein over creatinine ratio ranged between
0.35 and 1.58.
Sections of controls and patients were all positive for
1(IV), with an uninterrupted staining pattern of the
EBM. The EBM in the control sections was also uni-
formly positive for 5(IV).
5(IV) was also normally distributed in two patients
with proteinuria; in the remaining three patients with
proteinuria, the expression ratio of the 5(IV) chain in
the EBM was 35%, 47%, and 48%. Of the 17 patients
without proteinuria, two displayed complete absence of
the 5(IV) chain along the EBM (age, 16 and 19 years
at skin biopsy), 10 displayed an expression ratio between
18% and 65% (age, 4 to 64 years), while the remaining
five had normal staining of the EBM (expression ratio
100%; age, 2 to 46 years) (Table 2).
There was no correlation between the 5(IV) distribu-
tion in the EBM and the degree of proteinuria (r  0.2).
Besides, there was no correlation between the 5(IV)
distribution in the EBM and the age at skin biopsy (r 
0.7) Interestingly, immunohistochemical staining of the
skin for 5(IV) was concordant with that found in the
GBM in three of the four investigated cases (two with
a normal pattern and one with negative 5(IV) chain
distribution), while it diverged substantially in the re-
maining case (normal in the GBM and negative in the
EBM) (Table 2).
We could not find any clear correlation between the
5 immunostaining in the EBM and the mutations identi-
fied in the COL4A5 gene. Mutations are described in
Table 1.
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DISCUSSION
Our data show that, as expected, X-linked Alport syn-
drome female patients are very mildly affected. They
also show that 5(IV) chain staining in the EBM does
not correlate with the degree of proteinuria, which re-
flects the severity of glomerular involvement.
Nakanishi et al [11] reported a negative correlation
between the degree of proteinuria and the distribution of
the 5(IV) chain in the EBM. This apparent discrepancy
with our results could well be due to the relatively few
patients in both series (25 and 22, respectively), but other
explanations are also possible.
In the Japanese study, only patients with segmental
distribution were analyzed, while the expression ratio of
the 5(IV) chain distribution in our patients ranged from
0% to 100%. If the presence of 5 staining in the EBM
is inversely correlated with renal involvement, one could
expect female Alport syndrome patients with totally ab-
sent staining to have significant glomerular involvement.
In our experience, this is not the case because two of
our patients, 16 and 19 years old, had neither 5(IV)
chain staining in the EBM nor proteinuria and one of
them only showed intermittent microhematuria. Two
years after skin biopsy, these two patients still have no
proteinuria. Conversely, our patient with the highest de-
gree of urinary protein/creatinine ratio (patient 6) had
normal staining of the 5(IV) chain in the EBM. More-
over, our patients without proteinuria show a variable
distribution of the 5(IV) chain in the EBM, ranging
from 18% to 100%. In particular, four of them, older
than 40 years, showed a distribution of the 5(IV) chain
in the EBM between 18% and 40%. Finally, patients
17L and 18L are two sisters with the same mutation, 33
and 31 years old, who have only microhaematuria, but
with 100% and 35% of 5(IV)-positive distribution in
the EBM, respectively. This suggests that the difference
in the 5(IV) cutaneous staining is probably due to a
different lyonization, but also that this is not strictly
correlated with renal involvement.
Another difference that may account for our different
results could be that renal involvement of our population
is, on average, less severe (23% of patients with protein-
uria vs. 60%).
We cannot totally exclude that differences in the re-
sults of the two studies may be due, at least in part, to
the fact that different antibodies have been used, even
though this appears very unlikely. Interestingly, recent
evidence exists that accessibility of specific target re-
gion(s) of the 3(IV) NC1 domain is of crucial impor-
tance for antibody recognition [13]; although this has not
been demonstrated for5(IV), it suggests that antibodies
directed against different epitopes located within the
same region may react differently.
Our results confirm what has already been reported
in a dog model of X-linked Alport syndrome [14], where
the authors demonstrated no relationship between the
EBM 5(IV) expression and urinary protein excretion.
To our knowledge, data on the concordance of 5(IV)
distribution in the EBM and GBM are scant [11, 15]. In
four of our cases, the immunohistochemical study for
the 5(IV) chain in the GBM was performed before skin
biopsy (Table 2). 5(IV) distribution is discordant in
only one patient, where it was normal in the kidney and
totally negative in the skin. Moreover, in patient 8, even
if the 5(IV) chain was negative in the kidney and in
the skin, proteinuria was absent at the age of 21 years.
We have two possible explanations for this. The first is
that alterations of the epitopes in the NC domain did
not allow a positive staining of the 5(IV) either in the
EBM or in the GBM, but the protein was correctly incor-
porated in the renal network and this could explain a
mild renal disease. The other hypothesis is that the sever-
ity of renal disease does not depend on the 5(IV) distri-
bution in the GBM, but on the distribution of the other
 chains, specifically 3 and 4. As a matter of fact, in
patient 8, both 3 and 4 chains in GBM show a normal
distribution. In this case, our findings suggest that 5(IV)
is not a reliable indicator of the severity of renal disease.
In this regard, Van der Loop et al [16] reported a male
patient with a COL4A5 frameshift mutation, a negative
distribution of the 5(IV) chain in the EBM and a mild
clinical picture. They hypothesized that the negative
staining of the 5(IV) chain in the EBM could either
have been due to the absence or to the alteration of the
epitopes in the NC domain and not of the entire protein.
It could be possible for a mutation in the COL4A5 to
have different effects in the COL4A3-COL4A4-COL4A5
network in the GBM compared with the COL4A5-
COL4A6 network in the EBM. We can speculate that,
despite the absence of the 5(IV) chain in the skin, in
the kidney the protein could sometimes be correctly in-
corporated in the renal network, thus explaining milder
renal involvement. Moreover, the X-inactivation is not
similar in all tissues. In fact, the X-inactivation pattern
in normal females can vary widely in different tissues
from the same individual. This phenomenon is particu-
larly true for tissues with different embryonic origin, that
is the case of skin and kidney originated, respectively,
from ectoderm and mesoderm [17].
Finally, we cannot exclude that different mutations in
the COL4A5 gene in the two series of patients (the Japa-
nese and the Italian) could be responsible of such differ-
ent results.
CONCLUSION
In our experience, skin biopsy is a good alternative
diagnostic tool, especially in very young patients. We
have performed 54 skin biopsy from 45 families with
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X-linked Alport syndrome followed in our center: 18%
of the males and 30% of the females present a normal
distribution of the 5(IV) chain in the EBM on classical
immunofluorescence.
Despite this fact, skin biopsy should now be considered
as the first diagnostic step, especially in children. More-
over, our results suggest that the distribution of 5(IV)
in the EBM cannot be considered a prognostic indicator
of renal involvement in female patients with X-linked
Alport syndrome. Conclusive results will probably only
be obtained with a larger series of patients.
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